Digital Health Canada

digitalhealthcanada.com

Digital Health Canada connects, inspires, and educates the digital health professionals creating the future of health in Canada. Our members are a diverse community of accomplished, influential professionals working to make a difference in advancing healthcare through information technology. Digital Health Canada fosters network growth and connection; brings together ideas from multiple segments for incubation and advocacy; supports members through professional development at the individual and organizational level; and advocates for the Canadian digital health industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

news image

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More

Cell and Gene Therapy

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

news image

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More

Industrial Impact, Medical

ASAHI KASEI BIOPROCESS AMERICA AND GEMINIBIO ENTER STRATEGIC PARTNERSHIP TO ADVANCE APPLICATION OF INLINE BUFFER FORMULATION

businesswire | April 20, 2023

news image

Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry. Asahi Kasei Bioprocess, with decades of expertise in IBF and the developers of the award-winning MOTIV™ system, and GeminiBio, with industry leading bioprocess liquid manufacturing capabilities, are combining two high-efficiency so...

Read More

AMYRIS COLLABORATES WITH INFECTIOUS DISEASE RESEARCH INSTITUTE TO ADVANCE A NOVEL RIBONUCLEIC ACID VACCINE PLATFORM WITH COVID-19 VACCINE

Amyris | October 23, 2020

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vacci...

Read More
news image

GILEAD TO ACQUIRE IMMUNO-ONCOLOGY COMPANY FORTY SEVEN FOR $4.9 BILLION

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...

Read More
news image

Cell and Gene Therapy

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More
news image

Industrial Impact, Medical

ASAHI KASEI BIOPROCESS AMERICA AND GEMINIBIO ENTER STRATEGIC PARTNERSHIP TO ADVANCE APPLICATION OF INLINE BUFFER FORMULATION

businesswire | April 20, 2023

Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry. Asahi Kasei Bioprocess, with decades of expertise in IBF and the developers of the award-winning MOTIV™ system, and GeminiBio, with industry leading bioprocess liquid manufacturing capabilities, are combining two high-efficiency so...

Read More
news image

AMYRIS COLLABORATES WITH INFECTIOUS DISEASE RESEARCH INSTITUTE TO ADVANCE A NOVEL RIBONUCLEIC ACID VACCINE PLATFORM WITH COVID-19 VACCINE

Amyris | October 23, 2020

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vacci...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us